These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16936428)

  • 21. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension.
    Heran BS; Wong MM; Heran IK; Wright JM
    Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD003822. PubMed ID: 18843650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA; McVoy HJ; Kaul AF
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
    Grosso AM; Bodalia PN; Macallister RJ; Hingorani AD; Moon JC; Scott MA
    Int J Clin Pract; 2011 Mar; 65(3):253-63. PubMed ID: 21284790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure, glycemia and the HOMA-IR index in non-diabetic patients.
    Yang Y; Wei RB; Xing Y; Tang L; Zheng XY; Wang ZC; Gao YW; Li MX; Chen XM
    Metabolism; 2013 Dec; 62(12):1858-66. PubMed ID: 24050270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D
    Can J Cardiol; 2005 May; 21(7):569-75. PubMed ID: 15940354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure.
    Erhardt LR
    Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T
    Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension.
    Miller LA; Wade R; Dai D; Cziraky MJ; Ramaswamy K; Panjabi S
    Curr Med Res Opin; 2010 Jun; 26(6):1307-20. PubMed ID: 20370377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of antihypertensive therapy in new users of angiotensin II-receptor blockers.
    Young CH; Zhang K; Poret AW
    Am J Health Syst Pharm; 2005 Nov; 62(22):2381-5. PubMed ID: 16278329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.
    Simons WR
    Pharmacoeconomics; 2003; 21(1):61-74. PubMed ID: 12484804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
    Marshall TG; Lee RE; Marshall FE
    Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What have we learned from the current trials?
    Abbott KC; Bakris GL
    Med Clin North Am; 2004 Jan; 88(1):189-207. PubMed ID: 14871059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amlodipine versus Angiotensin-receptor blockers for nonhypertension indications.
    Kalus JS; White CM
    Ann Pharmacother; 2002 Nov; 36(11):1759-66. PubMed ID: 12398574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.